Navigation Links
AstraZeneca Medicare Part D Patient Assistance Program No Longer Requires Co-Pays
Date:12/8/2009

WILMINGTON, Del., Dec. 8 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that patients enrolled in the company's Medicare Part D prescription savings program will no longer pay co-pays for their medicines through the program.

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO )

Prescriptions also now will be mailed to patients' homes or physician's offices under the changes to the AZ&Me(TM) Prescription Savings program for people with Medicare Part D. The changes will take effect Jan. 1, 2010.

"These changes will better serve Medicare Part D enrollees by making it easier for them to access the medicines they need," said Rich Fante, US President, AstraZeneca Pharmaceuticals LP. "This prescription savings program and these latest improvements reflect our ongoing commitment to patient health."

Currently, patients enrolled in the program fill their AstraZeneca prescriptions at retail pharmacies and have a co-pay of between $15 and $25, depending on their qualifying income. The elimination of a co-pay will save approximately 30,000 patients enrolled in the program a total of $3 million each year.

Program Details

Eligible patients can enroll in the AZ&Me(TM) Prescription Savings program for people with Medicare Part D at any time in the calendar year, but must meet program requirements in order to start utilizing the benefit.

The AZ&Me(TM) Prescription Savings program for people with Medicare Part D is one of three distinct prescription savings programs in the AZ&Me Prescription Savings Program suite. Other AZ&Me Prescription Savings Programs include a plan for individuals without insurance and one for healthcare facilities.

To learn if you qualify for the AZ&Me Prescription Savings Programs, please visit www.AZandMe.com or call 1-800-AZandMe. Program specialists are available Monday through Friday between the hours of 9:00 AM and 5:00 PM EST.

Other prescription savings programs are available regardless of which medications your doctors prescribe. To find out more about the more than 475 savings programs covering 2,500 medications, please visit www.pparx.org or call 1-888-4PPA-NOW (1-888-477-2669).

NOTES TO EDITORS:

About AstraZeneca

AstraZeneca is engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and in the supply of healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with global healthcare sales of $31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.5 billion healthcare business.

For more information about AstraZeneca in the US or our AZ&Me(TM) Prescription Savings programs, please visit: www.astrazeneca-us.com.

SOURCE AstraZeneca


'/>"/>
SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. U.S. Court of Appeals Upholds AstraZeneca AWP Settlement
2. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
3. Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor
4. Jubilant Enters Research Collaboration With AstraZeneca
5. AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
6. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
7. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
8. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia
9. AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA
10. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease
11. AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... , Sept. 8, 2017 Dealmed Medical ... independent supplier of medical equipment, supplies, drugs, vaccines, and ... has entered into an agreement to acquire Vantage Medical ... based in Holtsville, New York . ... in supplying new and emerging medical practices, will operate ...
(Date:9/7/2017)... Sept. 7, 2017 NuvoAir (formerly called ... announced today a partnership with Novartis Pharma AG to distribute ... position as the leading mobile spirometry platform and Novartis, commitment ... ... ...
(Date:9/6/2017)...   PDI , a leader in infection prevention ... educational session focused on the role of chlorhexidine gluconate ... the 2017 Annual Scientific Meeting of the Association for ... the Phoenix Convention Center in ... will also feature PDI,s Prevantics® Device Swab ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... September 21, 2017 , ... The American ... Health Services for professionals in the addiction treatment industry entitled: Special Investigations ... , Insurance companies and state and federal governments are increasingly scrutinizing the addiction ...
(Date:9/21/2017)... ... 21, 2017 , ... Hair restoration surgery is having a ... the International Society of Hair Restoration Surgery (ISHRS). The worldwide volume ... with 635,189 procedures performed in 2016. , "Like other forms of cosmetic ...
(Date:9/21/2017)... , ... September 21, 2017 , ... Bill Howe Plumbing’s ... its customers, and give back to the community. For over 37 years, they have ... successful companies serving plumbing in San Diego. They were chosen as the ...
(Date:9/21/2017)... ... September 21, 2017 , ... Innovatum ... at the Global GS1 Healthcare Conference 2017 in Chicago, IL on October 17-19, ... ensuring label quality and improving patient safety. , Microscan , a ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... and highly accurate cancer screening tests, has received two prestigious recognitions that acknowledge ... survival rates. , Preora has been named a Top 100 Finalist ...
Breaking Medicine News(10 mins):